Skip to main content

Table 2 Mutations of abnormally expressed driver genes

From: Methylation-directed regulatory networks determine enhancing and silencing of mutation disease driver genes and explain inter-patient expression variation

Mutation type

Driver gene

Fraction (%) of tumors with coding mutations

Fraction (%) of tumors with abnormal expressiona

Expression variation explainedb

Methylation-expression associations

Regulatory

FBXW7

0

100

Yes

Negative

SMO

0

95.8

Yes

Both

SOX9

0

79.2

Yes

Positive

FGFR2

0

79.2

Yes

Negative

CASP8

0

70.8

Yes

Positive

TNFAIP3

0

70.8

Yes

Both

AR

0

70.8

Yes

Negative

CHEK2

0

66.7

Yes

Negative

H3F3A

0

54.2

Yes

Both

ABL1

0

45.8

Yes

Both

DAXX

0

29.2

Yes

Both

MSH6

0

29.2

Yes

MSH6

ZIC2

0

12.5

Yes

Negative

JAK1

0

8.3

Yes

Both

U2AF1

0

8.3

Yes

Positive

CTNNB1

0

8.3

Yes

Negative

MLH1

0

8.3

Yes

Negative

SOCS1

0

4.2

Yes

Both

SRSF2

0

4.2

Yes

Both

SMAD2

0

4.2

Yes

Negative

VHL

0

4.2

Yes

Negative

Regulatory and coding

CDKN2C

5.3

100

Yes

Negative

BRCA1

21.1

83.3

Yes

Both

TRAF7

5.3

41.7

Yes

Positive

AKT1

5.3

20.8

Yes

Positive

PBRM1

5.3

12.5

Yes

Both

MSH2

10.5

8.3

Yes

Both

FUBP1

5.3

8.3

Yes

Negative

MEN1

5.3

4.2

Yes

Both

CREBBP

10.5

4.2

Yes

Positive

PRDM1

10.5

0.8

Yes

Both

Coding

TP53

47.0

100

No

-

  1. aTwo-fold or more expression differences from normal brain samples
  2. bHave a verified methylation-based model of expression variation